InvestorsHub Logo
Followers 32
Posts 4245
Boards Moderated 0
Alias Born 07/25/2007

Re: wantprofits post# 767

Monday, 01/13/2020 3:43:41 PM

Monday, January 13, 2020 3:43:41 PM

Post# of 977
Below is what I wrote right after the FTSV data came out and that success initial drove TRIL higher. The data for TRIL's dose escalation trial did the same. I wouldn't be surprised to see TRIL's stock drop a decent amount but that won't after my long term view. I don't jump in and out of stocks, I invest. If I see an opportunity to recoup some of my initial investments then I will sell some to preserve capital, which is job one for investors. Now run along as with each post you when like a bitter burned short.

{{The shame of it for me was I planned to buy both FTSV and TRIL to cover the macrophage activation pathway. I bought some FTSV at $12 but bought more TRIL as the former had some issues with red blood cell depletion. However, that changed when FTSV used a pre-loading regimen that reduced the effects on red cells. I almost loaded up in FTSV when it fell below $7 but held off as it started to rise as I hope it would drop back. It didn't so that was lost opportunity for me.

As far as TRIL, I didn't have a great deal of money in it so didn't sell off as it cratered to lock in some losses to offset other gains. Once the FTSV results were announced I felt it was good news for TRIL. Once TRIL started to rebound I doubled my shares of TRIL yesterday at $0.45. TRIL is still a big risk due to money concerns but some positive trial data in the spring could juice the stock or a continued FTSV updraft swing makes it a bit less risky. If the latter cause TRIL to keep rising, I might sell some in January to lock in some losses for 2020 and get back some of my newly invested money.}}

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152784137